Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH.

For detailed information, see the below URL.

http://www.globenewswire.com/news-release/2020/10/12/2107044/0/en/Inventiva-receives-FDA-Breakthrough-Therapy-designation-for-lead-drug-candidate-lanifibranor-in-NASH.html

Lanifibranor is a PPAR agonist with moderate and well-balanced activity on the three PPAR isoforms (a, g, σ) This compound is also currently undergoing Phase 2 trials.
We are looking forward to future clinical results.